post

Old Doc, New Data: Mild asthma strategies

Mild asthma is a disease that every GP manages most days. We are guided by our National Asthma Council recommendations in the treatment of simple, mild asthma. For many patients, the use of intermittent short-acting bronchodilators is the easiest and usually an adequate strategy. Some patients with more frequent symptoms will require some form of […]

post

Paediatric Status Epilepticus Debate

Welcome back – as promised this is the bonus segment that was too good to leave in the Journal Club this month. Justin and I invited Dr Damian Roland back onto the podcast to discuss the new evidence which may guide our management of status epilepticus in children. Dr Damian Roland is an Emergency Paediatric […]

post

First10EM Journal Club: June 2019

Welcome back to the Journal Club with Justin Morgenstern. This month I have a special bonus segment for you… but first, you have to go through all the usual cacophony of intellectual curiosity that Justin and I seem to indulge in periodically. Below are the papers that made the podcast this month for your reading […]

post

I: Vancomycin & the Nephrocidal Maniacs

Vancomycin was first isolated in 1953 by Edmund Kornfeld from a soil sample collected from the jungles of Borneo by a missionary. It is produced by the soil bacterium Amycolatopsis orientalis. It was first licensed for use in patients with penicillin resistant Staph infections in 1958. Yes, vancomycin has been around longer than the Beatles! […]

post

CREDENCE Trial PODCAST: Can-I-get-a-flozin?

The CREDENCE trial was published in the NEJM last month and it has made some waves in the world of diabetes management. The headlines state that this SGLT2 drug can reduce the progression of diabetic nephropathy. That is big news indeed. So, what do I think about this new data for a drug that had […]